Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

DCPH Stock Forecast

Deciphera Pharmaceuticals stock forecast is as follows: an average price target of $26.32 (represents a 2.85% upside from DCPH’s last price of $25.59) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

DCPH Price Target

The average price target for Deciphera Pharmaceuticals (DCPH) is $26.32 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $25.00. This represents a potential 2.85% upside from DCPH's last price of $25.59.

DCPH Analyst Ratings

Hold

According to 10 Wall Street analysts, Deciphera Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for DCPH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Deciphera Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Apr 30, 2024	Peter Lawson	Barclays	$26.00	$25.27	2.89%	1.60%
Apr 29, 2024	Eun Yang	Jefferies	$25.60	$25.30	1.21%	0.04%
Apr 29, 2024	Christopher Raymond	Raymond James	$25.00	$25.29	-1.15%	-2.31%
Apr 29, 2024	Christopher Raymond	Raymond James	$25.60	$25.25	1.41%	0.04%
Feb 07, 2023	-	Leerink Partners	$30.00	$16.71	79.53%	17.23%
Jan 04, 2023	-	Leerink Partners	$28.00	$15.94	75.66%	9.42%
Jan 04, 2023	-	Barclays	$9.00	$15.94	-43.54%	-64.83%
Sep 12, 2022	-	H.C. Wainwright	$25.00	$18.08	38.27%	-2.31%
Aug 05, 2022	-	H.C. Wainwright	$20.00	$16.58	20.63%	-21.84%

Row per page

Go to

The latest Deciphera Pharmaceuticals stock forecast, released on Apr 30, 2024 by Peter Lawson from Barclays, set a price target of $26.00, which represents a 2.89% increase from the stock price at the time of the forecast ($25.27), and a 1.60% increase from DCPH last price ($25.59).

Deciphera Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	4
Avg Price Target	-	-	$25.55
Last Closing Price	$25.59	$25.59	$25.59
Upside/Downside	-100.00%	-100.00%	-0.16%

In the current month, the average price target of Deciphera Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Deciphera Pharmaceuticals's last price of $25.59. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Apr 29, 2024	Barclays	Underweight	Equal-Weight	Upgrade
Apr 29, 2024	JMP Securities	Market Outperform	Market Perform	Downgrade
Apr 29, 2024	Guggenheim	Buy	Neutral	Downgrade
Apr 29, 2024	Jefferies	-	Hold	Downgrade
Apr 29, 2024	Piper Sandler	Overweight	Neutral	Downgrade
Oct 30, 2023	Piper Sandler	-	Overweight	Upgrade
Aug 10, 2023	Raymond James	-	Buy	Upgrade
Feb 07, 2023	SVB Leerink	Outperform	Outperform	Hold
Jan 06, 2023	JonesTrading	-	Hold	Upgrade
Jan 04, 2023	William Blair	-	Outperform	Initialise

Row per page

Go to

Deciphera Pharmaceuticals's last stock rating was published by Barclays on Apr 29, 2024. The company Upgrade its DCPH rating from "Underweight" to "Equal-Weight".

Deciphera Pharmaceuticals Financial Forecast

Deciphera Pharmaceuticals Revenue Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19
Revenue	-	-	-	-	-	-	-	-	$48.29M	-	-	$33.45M	$36.34M	-	-	$29.22M	$24.20M	-	-	$25.16M	$19.49M	-	-	$62.00K	-	-	-
Avg Forecast	$72.50M	$62.53M	$55.60M	$50.40M	$54.83M	$53.33M	$49.46M	$46.20M	$45.93M	$39.45M	$36.09M	$35.69M	$35.97M	$33.08M	$30.56M	$26.88M	$23.41M	$23.47M	$21.93M	$22.46M	$18.65M	$6.71M	$877.78K	$56.98K	$1.25M	$454.55K	$2.00M
High Forecast	$72.50M	$62.53M	$55.60M	$50.40M	$54.83M	$53.33M	$51.95M	$46.20M	$47.26M	$41.44M	$36.09M	$35.69M	$35.97M	$33.08M	$30.56M	$26.88M	$23.41M	$23.47M	$21.93M	$22.46M	$18.65M	$6.71M	$877.78K	$68.38K	$1.25M	$454.55K	$2.00M
Low Forecast	$72.50M	$62.53M	$55.60M	$50.40M	$54.83M	$53.33M	$45.19M	$46.20M	$42.94M	$37.59M	$36.09M	$35.69M	$35.97M	$33.08M	$30.56M	$26.88M	$23.41M	$23.47M	$21.93M	$22.46M	$18.65M	$6.71M	$877.78K	$45.59K	$1.25M	$454.55K	$2.00M
# Analysts	1	1	1	1	2	2	5	5	7	10	5	5	4	4	4	4	5	12	11	10	10	9	8	13	6	5	5
Surprise %	-	-	-	-	-	-	-	-	1.05%	-	-	0.94%	1.01%	-	-	1.09%	1.03%	-	-	1.12%	1.04%	-	-	1.09%	-	-	-

Deciphera Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 5 analysts is $46.20M, with a low forecast of $46.20M, and a high forecast of $46.20M. DCPH's average Quarter revenue forecast represents a -4.34% decrease compared to the company's last Quarter revenue of $48.29M (Dec 23).

Deciphera Pharmaceuticals EBITDA Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19
# Analysts	1	1	1	1	2	2	5	5	7	10	5	5	4	4	4	4	5	12	11	10	10	9	8	13	6	5	5
EBITDA	-	-	-	-	-	-	-	-	$-50.78M	-	-	$-53.26M	$-47.16M	-	-	$-46.89M	$-87.61M	-	-	$-60.37M	$-61.79M	-	-	$-69.89M	$-66.76M	-	-
Avg Forecast	$-72.50M	$-62.53M	$-55.60M	$-50.40M	$-54.83M	$-53.33M	$-49.46M	$-61.99M	$-45.93M	$-39.45M	$-36.09M	$-56.36M	$-95.08M	$-33.08M	$-30.56M	$-51.23M	$-23.41M	$-23.47M	$-21.93M	$-60.57M	$-18.65M	$-6.71M	$-877.78K	$-65.98M	$-1.25M	$-454.55K	$-2.00M
High Forecast	$-72.50M	$-62.53M	$-55.60M	$-50.40M	$-54.83M	$-53.33M	$-45.19M	$-49.59M	$-42.94M	$-37.59M	$-36.09M	$-45.08M	$-76.07M	$-33.08M	$-30.56M	$-40.99M	$-23.41M	$-23.47M	$-21.93M	$-48.45M	$-18.65M	$-6.71M	$-877.78K	$-52.78M	$-1.25M	$-454.55K	$-2.00M
Low Forecast	$-72.50M	$-62.53M	$-55.60M	$-50.40M	$-54.83M	$-53.33M	$-51.95M	$-74.39M	$-47.26M	$-41.44M	$-36.09M	$-67.63M	$-114.10M	$-33.08M	$-30.56M	$-61.48M	$-23.41M	$-23.47M	$-21.93M	$-72.68M	$-18.65M	$-6.71M	$-877.78K	$-79.18M	$-1.25M	$-454.55K	$-2.00M
Surprise %	-	-	-	-	-	-	-	-	1.11%	-	-	0.95%	0.50%	-	-	0.92%	3.74%	-	-	1.00%	3.31%	-	-	1.06%	53.41%	-	-

undefined analysts predict DCPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Deciphera Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Deciphera Pharmaceuticals Net Income Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19
# Analysts	1	1	1	1	2	2	5	5	7	10	5	5	4	4	4	4	5	12	11	10	10	9	8	13	6	5	5
Net Income	-	-	-	-	-	-	-	-	$-47.19M	-	-	$-45.96M	$-45.94M	-	-	$-46.11M	$-88.40M	-	-	$-61.30M	$-62.74M	-	-	$-72.81M	$-67.22M	-	-
Avg Forecast	$-27.09M	$-36.41M	$-40.78M	$-43.69M	$-44.25M	$-43.43M	$-46.25M	$-63.04M	$-50.70M	$-53.25M	$-54.18M	$-57.31M	$-95.93M	$-50.37M	$-57.49M	$-52.10M	$-120.52M	$-108.68M	$-100.93M	$-61.30M	$-101.05M	$-113.53M	$-119.46M	$-66.40M	$-100.69M	$-99.42M	$-96.74M
High Forecast	$-27.09M	$-36.41M	$-40.78M	$-43.69M	$-44.25M	$-43.43M	$-37.84M	$-50.43M	$-43.70M	$-48.89M	$-54.18M	$-45.85M	$-76.74M	$-50.37M	$-57.49M	$-41.68M	$-120.52M	$-108.68M	$-100.93M	$-49.04M	$-101.05M	$-113.53M	$-119.46M	$-53.12M	$-100.69M	$-99.42M	$-96.74M
Low Forecast	$-27.09M	$-36.41M	$-40.78M	$-43.69M	$-44.25M	$-43.43M	$-55.50M	$-75.65M	$-56.82M	$-59.37M	$-54.18M	$-68.77M	$-115.12M	$-50.37M	$-57.49M	$-62.52M	$-120.52M	$-108.68M	$-100.93M	$-73.56M	$-101.05M	$-113.53M	$-119.46M	$-79.68M	$-100.69M	$-99.42M	$-96.74M
Surprise %	-	-	-	-	-	-	-	-	0.93%	-	-	0.80%	0.48%	-	-	0.88%	0.73%	-	-	1.00%	0.62%	-	-	1.10%	0.67%	-	-

Deciphera Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DCPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Deciphera Pharmaceuticals SG&A Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19
# Analysts	1	1	1	1	2	2	5	5	7	10	5	5	4	4	4	4	5	12	11	10	10	9	8	13	6	5	5
SG&A	-	-	-	-	-	-	-	-	$39.15M	-	-	$31.45M	$32.20M	-	-	$28.32M	$37.15M	-	-	$30.75M	$30.07M	-	-	$23.94M	$23.74M	-	-
Avg Forecast	$124.47M	$107.36M	$95.46M	$86.53M	$94.13M	$91.56M	$84.91M	$38.08M	$78.86M	$67.73M	$61.97M	$34.61M	$61.76M	$56.80M	$52.47M	$46.14M	$40.18M	$40.29M	$37.64M	$38.56M	$32.02M	$11.51M	$1.51M	$97.83K	$2.15M	$780.39K	$3.43M
High Forecast	$124.47M	$107.36M	$95.46M	$86.53M	$94.13M	$91.56M	$89.18M	$45.69M	$81.14M	$71.15M	$61.97M	$41.54M	$61.76M	$56.80M	$52.47M	$46.14M	$40.18M	$40.29M	$37.64M	$38.56M	$32.02M	$11.51M	$1.51M	$117.40K	$2.15M	$780.39K	$3.43M
Low Forecast	$124.47M	$107.36M	$95.46M	$86.53M	$94.13M	$91.56M	$77.59M	$30.46M	$73.72M	$64.54M	$61.97M	$27.69M	$61.76M	$56.80M	$52.47M	$46.14M	$40.18M	$40.29M	$37.64M	$38.56M	$32.02M	$11.51M	$1.51M	$78.27K	$2.15M	$780.39K	$3.43M
Surprise %	-	-	-	-	-	-	-	-	0.50%	-	-	0.91%	0.52%	-	-	0.61%	0.92%	-	-	0.80%	0.94%	-	-	244.66%	11.06%	-	-

Deciphera Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $38.08M, based on 5 Wall Street analysts, with a range of $30.46M to $45.69M. The forecast indicates a -2.74% fall compared to DCPH last annual SG&A of $39.15M (Dec 23).

Deciphera Pharmaceuticals EPS Forecast

	Dec 25	Oct 25	Jul 25	Mar 25	Dec 24	Oct 24	Jul 24	Mar 24	Dec 23	Oct 23	Jul 23	Mar 23	Dec 22	Oct 22	Jul 22	Mar 22	Dec 21	Oct 21	Jul 21	Mar 21	Dec 20	Oct 20	Jul 20	Mar 20	Dec 19	Oct 19	Jul 19
# Analysts	1	1	1	1	2	2	5	5	7	10	5	5	4	4	4	4	5	12	11	10	10	9	8	13	6	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.56	$-0.60	-	-	$-0.79	$-1.51	-	-	$-1.06	$-1.11	-	-	$-1.36	$-1.31	-	-
Avg Forecast	$-0.31	$-0.42	$-0.47	$-0.50	$-0.51	$-0.50	$-0.53	$-0.55	$-0.58	$-0.61	$-0.62	$-0.59	$-0.56	$-0.58	$-0.66	$-0.90	$-1.38	$-1.24	$-1.16	$-1.07	$-1.16	$-1.30	$-1.37	$-1.25	$-1.15	$-1.14	$-1.11
High Forecast	$-0.31	$-0.42	$-0.47	$-0.50	$-0.51	$-0.50	$-0.43	$-0.55	$-0.50	$-0.56	$-0.62	$-0.59	$-0.56	$-0.58	$-0.66	$-0.90	$-1.38	$-1.24	$-1.16	$-1.07	$-1.16	$-1.30	$-1.37	$-1.25	$-1.15	$-1.14	$-1.11
Low Forecast	$-0.31	$-0.42	$-0.47	$-0.50	$-0.51	$-0.50	$-0.64	$-0.55	$-0.65	$-0.68	$-0.62	$-0.59	$-0.56	$-0.58	$-0.66	$-0.90	$-1.38	$-1.24	$-1.16	$-1.07	$-1.16	$-1.30	$-1.37	$-1.25	$-1.15	$-1.14	$-1.11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.94%	1.08%	-	-	0.88%	1.09%	-	-	0.99%	0.96%	-	-	1.08%	1.14%	-	-

According to undefined Wall Street analysts, Deciphera Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DCPH previous annual EPS of $NaN (undefined).

Deciphera Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PROC	Procaps Group	$0.61	$10.00	1539.34%	-
IRWD	Ironwood Pharmaceuticals	$4.02	$11.67	190.30%	Buy
AVDL	Avadel Pharmaceuticals	$10.72	$17.80	66.04%	Buy
AMPH	Amphastar Pharmaceuticals	$44.16	$66.00	49.46%	Buy
EVO	Evotec SE	$5.55	$8.00	44.14%	Buy
ANIP	ANI Pharmaceuticals	$55.25	$79.00	42.99%	Buy
COLL	Collegium Pharmaceutical	$29.22	$40.50	38.60%	Buy
ALKS	Alkermes	$27.55	$36.38	32.05%	Hold
NBIX	Neurocrine Biosciences	$117.62	$147.35	25.28%	Buy
PBH	Prestige Consumer Healthcare	$81.49	$89.50	9.83%	Buy
SUPN	Supernus Pharmaceuticals	$35.25	$38.00	7.80%	Buy
DCPH	Deciphera Pharmaceuticals	$25.59	$26.32	2.85%	Hold
PAHC	Phibro Animal Health	$24.11	$18.67	-22.56%	Buy

DCPH Forecast FAQ

Is Deciphera Pharmaceuticals a good buy?

No, according to 10 Wall Street analysts, Deciphera Pharmaceuticals (DCPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 40.00% of DCPH's total ratings.

What is DCPH's price target?

Deciphera Pharmaceuticals (DCPH) average price target is $26.32 with a range of $25 to $30, implying a 2.85% from its last price of $25.59. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Deciphera Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for DCPH stock, the company can go up by 2.85% (from the last price of $25.59 to the average price target of $26.32), up by 17.23% based on the highest stock price target, and down by -2.31% based on the lowest stock price target.

Can Deciphera Pharmaceuticals stock reach $40?

DCPH's average twelve months analyst stock price target of $26.32 does not support the claim that Deciphera Pharmaceuticals can reach $40 in the near future.

What are Deciphera Pharmaceuticals's analysts' financial forecasts?

Deciphera Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $203.82M (high $206.31M, low $199.55M), average EBITDA is $-220M (high $-203M, low $-234M), average net income is $-197M (high $-176M, low $-219M), average SG&A $308.68M (high $320.57M, low $293.75M), and average EPS is $-2.087 (high $-1.991, low $-2.193). DCPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $241.03M (high $241.03M, low $241.03M), average EBITDA is $-241M (high $-241M, low $-241M), average net income is $-148M (high $-148M, low $-148M), average SG&A $413.82M (high $413.82M, low $413.82M), and average EPS is $-1.693 (high $-1.693, low $-1.693).

Did the DCPH's actual financial results beat the analysts' financial forecasts?

Based on Deciphera Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $163.36M, beating the average analysts forecast of $157.16M by 3.94%. Apple's EBITDA was $-211M, beating the average prediction of $-178M by 18.63%. The company's net income was $-195M, missing the average estimation of $-215M by -9.52%. Apple's SG&A was $136.46M, missing the average forecast of $243.17M by -43.88%. Lastly, the company's EPS was $0, missing the average prediction of $-2.403 by -100.00%. In terms of the last quarterly report (Dec 2023), Deciphera Pharmaceuticals's revenue was $48.29M, beating the average analysts' forecast of $45.93M by 5.14%. The company's EBITDA was $-50.782M, beating the average prediction of $-45.934M by 10.56%. Deciphera Pharmaceuticals's net income was $-47.19M, missing the average estimation of $-50.697M by -6.92%. The company's SG&A was $39.15M, missing the average forecast of $78.86M by -50.36%. Lastly, the company's EPS was $0, missing the average prediction of $-0.58 by -100.00%